Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co.   Now that we have all this data,…

USA Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will see AI bring to pharma companies and patients in the short and long term, as well as use cases for the technology.…

USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with…

Opinion Meghann Chilcott, chief technology/marketing officer at Benzer Pharmacy provides insights for expanding point-of-care (POC) testing services in the US retail environment, and opportunities for improving patient outcomes and customer satisfaction in the process.   POC testing makes it possible for patients to receive the treatment or the advice they need…

Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes.   Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…

Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…

Cannabis OPINION: Keith Wolsko and Danielle Moore of cannabis industry recruitment specialists Simply Kind Solutions highlight the seismic recent growth of the USA’s burgeoning cannabis industry and the kinds of profiles that the industry is looking for.   We are witnessing the birth of the next great American industry. So, you…

USA As part of Women’s History Month, Chip Davis, president and CEO of the Association for Accessible Medicines highlights some of the most outstanding women that have worked in the generic pharmaceutical industry throughout history and pinpoints the women shaping today’s landscape for affordable and accessible medicines.   As we wrap…

Opinion Drug development in rare diseases is currently in a very exciting time. While much of the focus is on the scientific advances,  access to rare disease patients and well-designed clinical trials are also essential to evaluating new therapeutics. In this article, PJ Brooks, Program Director at the Office of Rare…

Opinion On International Women’s Day 2019, David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made to close the gender investment gap, touching on key trends and biases in venture capital funding and outlining why investing in women matters.   When women business owners pitch their…

Opinion Robin Toft is the Author of WE CAN™, the Executive Woman’s Guide to Career Advancement and founder and CEO of Toft Group Executive Search, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. In this article, she discusses the…

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…